[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-solid-tumors":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,73,99,122,143,164,184,204,231,254,278,300],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100342530","natural-history-and-biospecimen-acquisition-for-children-and-adults-with-rare-solid-tumors-100342530",false,"NCT03739827","Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors","* INCLUSION CRITERIA:\n* Cohort 1: Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year). There are no age restrictions beyond the neonatal period (4 weeks).\n\nOR\n\n-Cohort 2: Participants without a rare tumor who have a germline genetic variant that predisposes to a rare solid tumor\n\nOR\n\n-Cohort 3: Relatives of participants with diagnosis of rare solid tumors who do NOT have a known germline variant that predisposes to a rare solid tumor\n\nOR\n\n* Cohort 4: Parent\u002Fguardian of child participating in a focus group if not already enrolled on the study.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone",true,"ALL","4 Weeks",{"count":20,"type":21},10000,"ESTIMATED","OBSERVATIONAL","Background:\n\nApproximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments.\n\nObjective:\n\nTo better understand rare cancers and hereditary cancer syndromes.\n\nEligibility:\n\nPeople who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors.\n\nDesign:\n\nParticipants will be screened with questions about their medical history and\u002For that of their family members. They will give a saliva sample.\n\nParticipants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample.\n\nParticipants may also have:\n\n* Physical exam\n* Clinical photography\n* Blood, urine, saliva, and stool samples taken\n* Consultation with specialists\n* A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field.\n* Genetic testing\u002Fgenetic counseling.\n\nParticipants will be contacted once a year. They will answer updated questions about their medical and family history.\n\nParticipants will be asked to contact the study team if there are changes in their tumors.\n\nParticipants may be invited to join focus groups for people with the same diagnosis of rare tumors.\n\nParticipants may be invited to participate in other NIH protocols.\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\nRARE TUMOR LIST:\n\n1. Acinar cell carcinoma of the pancreas\n2. Adamantinoma\n3. Adenosqaumous carcinoma of the pancreas\n4. Adrenocortical carcinoma\n5. Alveolar soft part sarcoma\n6. Anaplastic Thyroid Cancer\n7. Angiosarcoma\n8. Atypical Teratoid Rhabdoid Tumor\u002FMRT\n9. Carcinoid\n10. Carcinoma of Unknown Primary\n11. Chondrosarcoma\n12. Chondromyxoid fibroma\n13. Chordoma\n14. Clear cell renal carcinoma\n15. Clear Cell Sarcoma\n16. Clear cell sarcoma of kidney\n17. Conventional chordoma\n18. Dedifferentiated chordoma\n19. Desmoid\n20. Desmoplastic small round cell tumor\n21. Epithelioid hemangioendothelioma\n22. Esthenioneuroblastoma\n23. Ewing Sarcoma\n24. Fibrolamellar carcinoma\n25. Fusion negative rhabdomyosarcoma\n26. Fusion positive renal cell carcinoma\n27. Fusion positive rhabdomyosarcoma\n28. Gastro-enteropancreatic neuroendocrine tumor\n29. Hepatoblastoma\n30. Hereditary Diffuse Gastric Cancer\n31. Inflammatory myofibroblastic tumor\n32. Kaposiform hemangioendothelioma\n33. Malignant ectomesenchymal tumor\n34. Malignant peripheral nerve sheath tumor\n35. Malignant triton tumor\n36. Medullary thyroid cancer\n37. Mixed acinar adenocarcinoma\n38. Mixed acinar neuroendocrine carcinoma\n39. Myxoid Liposarcoma\n40. Neuroblastoma\n41. Neuroendocrine tumors\n42. NUT midline carcinoma\n43. Osteosarcoma\n44. Pancreas ductal adenocarcinoma with squamous features\n45. Pancreatic acinar cell carcinoma\n46. Papillary renal cell carcinoma\n47. Paraganglioma\n48. Parosteal Osteosarcoma\n49. Periosteal Osteosarcoma\n50. Peripheral nerve sheath tumor\n51. Peripheral primitive neuroectodermal tumor\n52. Pheochromocytoma\n53. Pituitary cancer\n54. Poorly differentiated chordoma\n55. Renal medullary carcinoma\n56. Rhabdomyosarcoma\n57. Round cell Liposarcoma\n58. Schwannoma\n59. Sclerosing Epithelioid Fibrosarcoma\n60. SDH deficient GIST\n61. SMARCB1 deficient tumors\n62. SMARCA4 deficient tumors\n63. Synovial sarcoma\n64. Undifferentiated Sarcoma\n\n    \\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\n    \\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*",[25,26,27,28,29],"Malignant Solid Tumors","Other Neoplasms Solid Tumors","Pediatric Solid Tumor","Refractory Solid Tumors","Solid Tumor",[31,32,33,34],"Service to the Patients","Knowledge about the Nature of Cancer","Cancer Evaluations","Natural History","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-24","ACTUAL",{"date":41,"type":39},"2019-01-28",{"date":43,"type":21},"2032-03-31",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100564469","phase-2-phase-ii-study-of-asciminib-for-second-line-treatment-of-chronic-phase-chronic-myeloid-leukemia-100564469","NCT06629584","Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of Ph-positive (by cytogenetics or FISH) or BCR-ABL-positive (by PCR) CML in chronic phase and have received one prior line of therapy with a TKI.\n3. History of treatment failure defined as either:\n\n   * BCR::ABL1 \\>0.1% for patients with intolerance to first-line TKI\n   * Less than complete hematologic response (CHR) at ≥3 months\n   * No partial cytogenetic response at ≥3 months\n   * BCR::ABL1 ≥ 10% at if 3-6 months\n   * BCR::ABL1 ≥ 1% at ≥6 months\n   * Loss of CCyR or development of mutations or other clonal chromosomal abnormalities at any time during TKI treatment\n4. ECOG performance status ≤ 2.\n5. Adequate end organ function within 12 days before the first dose of asciminib treatment. Patients with mild to moderate renal and hepatic impairment are eligible if:\n\n   * Total bilirubin ≤ 3.0 x ULN without AST\u002FALT increase\n   * Aspartate transaminase (AST) ≤ 5.0 x ULN\n   * Alanine transaminase (ALT) ≤ 5.0 x ULN\n   * Serum lipase ≤ 1.5 x ULN. For serum lipase \\> ULN and ≤ 1.5 x ULN, value should be considered not clinically significant and not associated with risk factors for acute pancreatitis\n   * Alkaline phosphatase ≤ 2.5 x ULN\n   * Creatinine clearance ≥ 30 mL\u002Fmin as calculated using Cockcroft-Gault formula\n6. The effects of Asciminib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential must agree to use highly effective methods of contraception during dosing and for 30 days after study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Allowable methods of birth control:\n\n   * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n   * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before the start of study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n   * Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n   * Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C1%), for example hormone vaginal ring or transdermal hormone contraception.\n   * Sexually active males must use a condom during intercourse while taking the drug and for 30 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.\n\nExclusion Criteria:\n\n1. Patients with a history of T315I mutation.\n2. Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF \\\u003C 40% by echocardiogram or multi-gated acquisition (MUGA) scan.\n3. Patients with a history of myocardial infarction within the last 6 months or unstable\u002Funcontrolled angina pectoris or history of severe and\u002For uncontrolled ventricular arrhythmias. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third-degree AV block).\n4. Corrected QT interval (QTc) of \\> 450 milliseconds (ms) on baseline electrocardiogram (ECG or EKG) (using the Fridericia Formula)\n5. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:\n\n   * Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant\u002Fsymptomatic bradycardia.\n   * Concomitant medication(s) with a known risk to prolong the QT interval and\u002For known to cause Torsades de Pointes that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.\n6. Patients with known active infection with human immunodeficiency virus (HIV) or Hepatitis B or C.\n7. Patients with known conditions that would significantly affect the ingestion or gastrointestinal absorption of drugs administered orally.\n8. Nursing women, women of childbearing potential (WOCBP) with positive blood or urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (see inclusion criteria 8)\n9. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.\n10. ANC \\\u003C 500\u002Fmm3, platelet count \\\u003C 50,000 mm3.\n11. History of other active malignancy within 2 years prior to study entry except for previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively.\n12. Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study.\n\nPatients should have discontinued therapy with imatinib, bosutinib, dasatinib or nilotinib or other anti-leukemia therapy (except hydroxyurea), at least 48 hours prior to start of study therapy and recovered from any toxicity due to these therapies to at least grade 1. The use of hydroxyurea is allowed immediately prior to study entry.","18 Years",{"count":56,"type":21},40,"INTERVENTIONAL",[59],"PHASE2","This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.",[25],"2026-06-04",{"date":64,"type":39},"2026-06-08",{"date":66,"type":39},"2025-02-14",{"date":68,"type":21},"2028-12-31",{"name":70,"class":71},"M.D. Anderson Cancer Center","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":57,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100626522","phase-1-a-study-of-tak-505-in-adults-with-solid-tumors-100626522","NCT07436728","A Study of TAK-505 in Adults With Solid Tumors","A Phase 1\u002F2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Aged greater than or equal to (≥) 18 years or ≥ the local legal age of majority, as applicable, at the time of signing the main informed consent form (ICF).\n2. Criteria for disease state in dose escalation and cohort-expansion:\n\n   1. Tumor histologies during dose escalation (including potential participants in backfill cohort): Participants with histologically or pathologically confirmed locally advanced or metastatic solid tumors, who are either ineligible for or intolerant of standard therapies, have no approved therapy with demonstrated benefit available, or have exhausted all available standard therapies:\n\n\u003C!-- -->\n\n1. Gastric adenocarcinoma.\n2. Colorectal cancer (CRC).\n3. Non-small cell lung cancer (NSCLC) (both squamous and non-squamous).\n4. Head and neck squamous cell carcinoma (HNSCC). b) Tumor histologies during dose expansion: Participants will be eligible if they have histologically or pathologically confirmed, locally advanced or metastatic solid tumors, as follows:\n\n1\\. Metastatic or advanced squamous or non-squamous NSCLC:\n\n* Participants with no known activating mutations: have received platinum-based chemotherapy and anti-programmed death protein 1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) for locally advanced or metastatic disease (chemotherapy and anti-PD-1\u002FPD-L1 treatment can be received in combination or in sequence).\n* Participants with a known activating mutation with an approved and accessible target therapy (including but not limited to epidermal growth factor receptor \\[EGFR\\], anaplastic lymphoma kinase, ROS proto-oncogene 1, receptor tyrosine kinase, v-raf murine sarcoma viral oncogene homolog B1V600, rearranged during transfection, mesenchymal epithelial transition \\[MET\\] exon 14 skipping mutation, neurotrophic tyrosine receptor kinase, and kirsten rat sarcoma G12C) should have received the respective targeted therapy and 1 line of platinum-based chemotherapy and anti-PD-1\u002FPD-L1 (if appropriate).\n* Participants should have received no more than 3 prior lines of therapies for locally advanced or metastatic cancer.\n\n  2\\. CRC: adenocarcinoma\n* Participants who have received or been intolerant to treatment with either trifluridine\u002Ftipiracil (TAS-102), regorafenib or fruquintinib. Participants who have been treated with all are permitted. Participants must also have been previously treated with standard approved therapies, such as: fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if rat sarcoma (RAS) wild-type, an anti-EGFR therapy or checkpoint inhibitors, as clinically appropriate.\n* Participants should have received no more than 4 prior lines of therapies for locally advanced or metastatic cancer.\n\n  3\\. Gastric adenocarcinoma\n* Participants who have received or been intolerant to platinum\u002Ffluoropyrimidine doublet with or without anthracycline. Participants who are human epidermal growth factor receptor 2 (HER2) positive, PD-L1 positive or having microsatellite instability-high (MSI-H) should have received anti-HER2 and anti-PD-1\u002FPD-L1 treatment, respectively.\n* Participants should have received no more than 3 prior lines of therapies for locally advanced or metastatic cancer.\n\n  3\\. Confirmed PD-L1 positive by an FDA approved, Conformité Européene (CE)-marked, or other health-authority equivalent test in local lab. If historical PD-L1 status is not available, participants are eligible for pre-screening.\n\n  4\\. Tumor tissue: All participants must provide an existing formalin-fixed paraffin-embedded (FFPE) archival tumor sample taken within 24 months of the date of the main ICF. If the acquisition of FFPE blocks is not feasible, freshly cut slides from the eligible FFPE sample should be provided, and the slides need to have been cut within 3 months before the expected (Cycle 1 Day 1) C1D1. See the lab manual, which is provided separately, for further details. If an FFPE archival tumor sample is not available, tumor biopsy will be required before trial entry.\n\n  5\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Participants must have at least 1 lesion that meets the definition of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria (radiologically measured by the investigator). Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable\u002Ftarget lesions, unless treatment was ≥12 months prior to start of treatment and\u002For there has been demonstrated progression in that particular lesion.\n\n  7\\. Adequate bone marrow function as defined below:\n  1. Absolute neutrophil count (ANC) ≥1,000\u002F microliters(μL),\n  2. Platelet count ≥75,000\u002FμL\n  3. Hemoglobin ≥9.0 grams per deciliter (g\u002FdL). 8. Adequate renal and liver function as defined below:\n\n  \u003C!-- -->\n\n  1. Alanine aminotransferase (ALT)\u002F Aspartate aminotransferase (AST) less than equal to (≤) 3.0 × the upper limit of the normal range (ULN); for participants with hepatic metastases, ALT and AST)≤5 × ULN.\n  2. Total bilirubin ≤1.5 × ULN, except for participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits.\n  3. Creatinine clearance ≥45 mL\u002Fminute (calculated by Cockcroft-Gault formula). 9. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events \\[CTCAE\\] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and\u002For autoimmune endocrinopathies with stable endocrine replacement therapy.\n\n     10\\. Suitable venous access for the collection of trial-required blood sampling. 11. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥14 days, and meet the following criteria at the time of enrollment:\n\n  a) No concurrent treatment for CNS disease (for example, surgery, radiation, and corticosteroids ≥10 mg\u002Fd prednisone or equivalent).\n\n  b) No concurrent leptomeningeal disease or cord compression. Exclusion Criteria\n  1. History of known autoimmune disease, except for:\n\n     a) Vitiligo. b) Psoriasis not requiring systemic treatment for \\>1 year before receipt of TAK-505.\n\n     c) History of Graves' disease in participants now euthyroid for \\>4 weeks. d) Hypothyroidism managed by thyroid hormone replacement. e) Alopecia. f) Well-controlled diabetes type 1.\n  2. History of brain metastasis or leptomeningeal disease unless:\n\n     a) Brain metastases are stable on cranial imaging (that is, ≥4 weeks) following prior surgery, whole-brain radiation OR b) Received stereotactic radiosurgery and is off corticosteroids for brain metastases AND c) Is without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).\n  3. History of any of the following ≤6 months before the first dose of trial intervention:\n\n     a) Congestive heart failure New York Heart Association (NYHA) Grade III or IV. b) Unstable angina. c) Myocardial infarction. d) Unstable symptomatic ischemic heart disease. e) Uncontrolled hypertension despite appropriate medical therapy. f) Any ongoing symptomatic cardiac arrhythmias of Grade greater than (\\>) 2 (including acute atrial flutter\u002Ffibrillation, ventricular fibrillation, or ventricular tachycardia). Chronic, stable atrial fibrillation on stable anticoagulant therapy, including lowmolecular-weight heparin, is allowed.\n\n     g) Acute symptomatic pulmonary embolism, or symptomatic cerebrovascular events, or any other serious cardiac condition (for example, pericardial effusion or restrictive cardiomyopathy).\n\n     h) Left ventricular ejection fraction (LVEF) less than (\\\u003C) 50%, as measured by echocardiogram or multigated acquisition scan (MUGA) within 4 weeks before receiving the first dose of trial intervention.\n  4. History of hepatic encephalopathy.\n  5. Active diagnosis of a lung condition including:\n\n     a) Pneumonitis b) Interstitial lung disease c) Severe chronic obstructive pulmonary disease d) Idiopathic pulmonary fibrosis e) Other restrictive lung diseases f) Acute symptomatic pulmonary embolism g) Grade ≥2 pleural effusion not controlled by tap or requiring indwelling catheters.\n  6. Ongoing or active infection of Grade ≥2\n  7. Oxygen saturation \\\u003C90% on room air at screening or during the C1D1 predose assessment.\n  8. Inflammatory process that has not resolved for ≥4 weeks before the first dose of trial intervention. Participants with chronic low-grade inflammatory processes such as radiation induced pneumonitis are excluded regardless of duration.\n  9. Clinically significant gastrointestinal disorders including the following:\n\n     1. Gastrointestinal perforation or unhealed ulcerations \\\u003C6 months before trial intervention administration. Participants must have documented evidence (for example, upper endoscopy or colonoscopy) of a completely healed area of prior perforation.\n     2. Gastrointestinal bleeding \\\u003C2 months before trial intervention administration. Participants must have documented evidence (for example, from upper endoscopy or colonoscopy) of a completely healed area of prior bleeding.\n     3. Pancreatitis \\\u003C6 months before the initiation of trial intervention. Participants must have a computed tomography (CT) scan that is negative for evidence of remaining disease or normal pancreatic enzyme levels \\>4 weeks before the initiation of trial intervention.\n     4. Diverticulitis flare \\\u003C2 months before trial intervention administration. Participants must have a CT scan demonstrating no evidence of remaining disease before the initiation of trial intervention.\n     5. History of Crohn's disease or ulcerative colitis.\n  10. Vaccination with any live virus vaccine within 4 weeks or other vaccines within 2 weeks before the initiation of trial intervention. Inactivated annual influenza vaccination is allowed.\n  11. History of a bone marrow transplantation within the past 5 years or solid organ transplantation (as a recipient) and use of immunosuppressive agents.\n  12. Known hypersensitivity to TAK-505 or any excipient (acetate, arginine, histidine, methionine or polysorbate 80) contained in the drug or diluent formulation, or known hypersensitivity to tocilizumab.\n  13. Diagnosed with a second primary invasive malignancy not in remission for ≥3 years.\n\n      Exceptions include:\n      1. Nonmelanoma skin cancer\n      2. Cervical carcinoma in situ\n      3. Resected melanoma in situ\n      4. Malignancies considered indolent and never required therapy. This does not include lymphomas.\n      5. Others upon consultation and approval from the sponsor.\n  14. Known to be Human Immunodeficiency Virus (HIV) positive or hepatitis B or C positive as defined below:\n\n      1. Positive serology for HIV.\n      2. Positive hepatitis B surface antigen (HBsAg) test.\n      3. Positive hepatitis C virus (HCV) antibody test.\n  15. Received the following prior therapies before the planned start of TAK-505:\n\n      1. Cytotoxic chemotherapy, small-molecule inhibitors, cell therapy, radiation, interventional radiology procedure, or similar investigational therapies within ≤2 weeks or 5 half-lives, whichever is shorter.\n      2. Monoclonal antibodies including PD-1 checkpoint inhibitors (for example, pembrolizumab and nivolumab), antibody (Ab)-drug conjugates, radioimmunoconjugates, or similar therapies within ≤4 weeks.\n      3. Any anti-PD-L1 treatment, including PD-L1 checkpoint inhibitors (for example, atezolizumab and durvalumab) and antibody-drug conjugates, within 120 days.\n      4. Not recovered to Grade 1 or baseline or established as sequelae from all toxic effects of previous therapy (except alopecia, neuropathy, or autoimmune endocrinopathies with stable endocrine replacement therapy, or bone marrow parameters \\[any of Grade 1\u002F2 permitted if directly related to bone marrow involvement\\]).\n  16. Used corticosteroids or other immunosuppressive medication, concurrently or within 14 days of administration of TAK-505, except for:\n\n      a) Topical, intranasal, inhaled, ocular, or intra-articular corticosteroids. b) Physiologic doses of replacement steroid (for example, for adrenal insufficiency).\n\n      c) Steroid premedication for hypersensitivity reactions and antiemetic use. d) Stable steroid dose (established for ≥28 days before the first dose of TAK-505) for previously treated brain metastasis. Corticosteroid dose on C1D1 should be ≤15 mg\u002Fd of prednisone or equivalent.\n  17. Major surgery or traumatic injury within 8 weeks before the first dose of trial intervention.\n  18. Unhealed wounds from surgery or injury.\n  19. Any pre-existing medical or psychiatric condition or illness, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug or that would limit compliance with trial requirements or compromise ability to provide written informed consent.\n  20. Has a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of trial intervention.\n  21. Is capable of breastfeeding but does not agree to forego breastfeeding from the first dose of trial intervention through 180 days after the last dose of trial intervention.\n  22. Is a person of child-bearing potential (POCBP) but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) until 180 days after the last dose of trial intervention. Contraception methods may be considered highly effective if they can achieve a failure rate of \\\u003C1% per year when used consistently and correctly.\n  23. Is of male birth and fertile, and has partners of childbearing potential, but does not agree to use effective barrier contraception, that is, a condom, combined with at least 1 other form of acceptable contraception from signing of the main ICF until at least 180 days after the last dose of trial intervention.\n  24. Does not agree to refrain from donating gametes from signing of the main ICF until 180 days after the last dose of trial intervention.\n  25. Is a trial site employee, a site employee's immediate family member (for example, spouse, parent, child, and sibling), or is in a dependent relationship with a trial site employee who is involved in the conduct of this trial or may consent under duress.\n  26. Is considered to be vulnerable, as defined per local regulations and if exclusion is required by local regulations. Examples are persons under safeguard of justice, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care without their consent, persons admitted to a health or social establishment for purposes other than research, persons of full age who are subject to a legal protection measure (guardianship or curatorship), and persons unable to express their consent.\n  27. Is unable or unwilling to comply with clinic visits and procedures outlined in the trial protocol.\n  28. Is unwilling to provide informed consent\u002Fage-appropriate assent.\n  29. Baseline prolongation of the QT interval with Fridericia correction method (QTcF) (for example, repeated demonstration of corrected QT interval \\[QTc\\] ≥480 ms, history of congenital long QT syndrome, or torsades de pointes). If patients are taking medications known to prolong the QTc at screening, patients may continue to take these medications as long as their baseline QTcF is \\\u003C480 ms that are receiving such medications. Participants may not start using such medications on C1D1.",{"count":81,"type":21},151,[83,59],"PHASE1","Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable).\n\nThis study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC).\n\nThe main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).",[25],[87],"Drug Therapy","2026-05-13",{"date":90,"type":39},"2026-05-14",{"date":92,"type":39},"2026-05-11",{"date":94,"type":21},"2030-08-18",{"name":96,"class":97},"Takeda","INDUSTRY",15,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":57,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100576117","phase-1-one-trial-of-jcxh-211-intratumoral-injection-combined-with-anti-pd-1-antibody-in-patients-with-malignant-solid-tumors-100576117","NCT06781125","One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","A Phase I\u002FII Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients, aged 18 to 75 years;\n2. patients with malignant solid tumors confirmed by pathology and\u002For cytology who have progressed or are intolerant to standard treatment (except best supportive care); Including patients who have received prior anti-PD-1 antibody therapy; patients who have been approved as eligible for Toripalimab:\n3. General condition score ECOG 0 \\~ 1;\n4. Expected survival of more than 3 months;\n\nExclusion Criteria:\n\n1. Known or suspected allergy to the ingredients of the study drug or its analogues; allergic history to another monoclonal antibody;\n2. patients who have previously received IL-12 therapy (alone or as part of a treatment regimen), except those who have participated in tolerance to a single intratumoral injection;\n3. patients who have previously received treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or have received treatment directed at another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137), and discontinued treatment due to Grade 3 or higher immune-related adverse events (irAEs);","75 Years",{"count":108,"type":21},72,[83,59],"This is an open-label, dose-escalation and dose-expansion Phase I \u002FII clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.",[25],"NOT_YET_RECRUITING","2026-03-20",{"date":115,"type":39},"2026-03-24",{"date":117,"type":21},"2026-03-18",{"date":119,"type":21},"2028-06-30",{"name":121,"class":97},"Immorna Biotherapeutics, Inc.",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":129,"targetDuration":4,"studyType":57,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":72},"100595117","phase-2-a-trial-of-shr-4849-combined-with-other-antitumor-drugs-in-patients-with-malignant-solid-tumors-100595117","NCT07028281","A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","A Multicenter, Open-label, Phase II Clinical Study of SHR-4849 Injection Combined With Other Antineoplastic Drugs in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Subject has provided informed consent prior to initiation of any study-procedures\n2. Age from 18 to 75 years old at the time of signing the informed consent\n3. Histologically or cytologically confirmed solid tumors\n4. At least one measurable lesion was identified per RECIST 1.1\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n6. Has a life expectancy of at least 3 months.\n7. Adequate organ function\n8. Subjects of both genders of child-bearing potential were required to use highly effective contraception from the time they provided written informed consent until 8 months after the last dose of the trial drug\n\nExclusion Criteria:\n\n1. Subjects with active central nervous system (CNS) metastasis.\n2. Subjects with a history of malignant tumors within 5 years prior to the first dose\n3. Subjects with uncontrolled cancer pain.\n4. Subjects with severe cardiovascular disease.\n5. Subjects with clinically significant hemorrhage\n6. Subjects with uncontrolled pleural effusion, peritoneal effusion and pericardial effusion\n7. Subjects highly suspected of interstitial lung disease\n8. Subjects with serious infection within 4 weeks prior to the first dose\n9. Known history of human immunodeficiency virus (HIV)，active hepatitis B virus or hepatitis C virus infection.\n10. The adverse events of previous antineoplastic therapy did not recover to NCI-CTCAE≤ grade 1\n11. Subjects who received anti-cancer treatment within 4 weeks prior to the first dose\n12. Subjects who received major surgery within 4 weeks prior to the first dose\n13. Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose.\n14. Female subjects who were pregnant, lactating, or planned to become pregnant during the study period\n15. Known allergic to any component of investigational drugs\n16. Alcohol abuse, drug abuse, other serious medical conditions (including mental illness) requiring combined treatment, and other conditions that may affect subject safety or data collection.\n17. Based on the investigator's judgment, subjects with other conditions that may affect study results, interfere with study procedures,",{"count":130,"type":21},120,[59],"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.",[25],"2026-02-27",{"date":136,"type":39},"2026-03-03",{"date":138,"type":39},"2025-07-08",{"date":140,"type":21},"2028-12",{"name":142,"class":97},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":150,"targetDuration":4,"studyType":57,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":163},"100613549","phase-2-a-trial-of-shr-7787-injection-combined-with-other-anti-tumor-drugs-in-patients-with-malignant-solid-tumors-100613549","NCT07268040","A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;\n2. Patients with histologically or cytologically confirmed unresectable solid tumors;\n3. At least one measurable lesion was identified per RECIST 1.1;\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;\n5. Adequate organ functions as defined per protocol;\n6. Minimum life expectancy of 3 months.\n\nExclusion Criteria:\n\n1. Patients with known active central nervous system (CNS) metastases;\n2. History of other malignancy within the past 5 years, with exceptions defined in the protocol;\n3. Patients with uncontrolled cancer pain;\n4. Patients with serious cardiovascular and\u002For cerebrovascular diseases;\n5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;\n6. Patients with Severe infections within 4 weeks prior to the first dose;\n7. Active pulmonary tuberculosis infection;\n8. History of immunodeficiency;\n9. History of autoimmune diseases;\n10. The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;\n11. Pregnant or nursing women, or planned to become pregnant during the study period;\n12. Known allergic to any component of investigational drugs.",{"count":151,"type":21},400,[59],"This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.",[25],"2026-01-08",{"date":157,"type":39},"2026-01-12",{"date":159,"type":39},"2025-12-23",{"date":140,"type":21},{"name":162,"class":97},"Shanghai Hengrui Pharmaceutical Co., Ltd.",2,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":171,"targetDuration":4,"studyType":57,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":72},"100572781","phase-1-a-phase-iii-clinical-study-of-shr-1681-for-injection-in-patients-with-advanced-solid-tumors-100572781","NCT06737731","A Phase I\u002FII Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","A Phase I\u002FII, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1681 for Injection in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;\n2. Subjects with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;\n3. Have at least one measurable tumor lesion per RECIST v1.1;\n4. ECOG performance score of 0-1;\n5. Life expectancy ≥ 3 months;\n6. Adequate bone marrow and organ function.\n\nExclusion Criteria:\n\n1. Subjects with active central nervous system metastases or meningeal metastases;\n2. History of serious cardiovascular and cerebrovascular diseases;\n3. Subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis;\n4. Severe infection within 4 weeks prior to the first dose;\n5. Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;\n6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.",{"count":172,"type":21},300,[83,59],"This study is an open-label, multicenter Phase I\u002FII clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.",[25],"2026-01-07",{"date":178,"type":39},"2026-01-09",{"date":180,"type":39},"2025-01-21",{"date":182,"type":21},"2027-07",{"name":142,"class":97},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":191,"targetDuration":4,"studyType":57,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":72},"100610594","phase-1-a-phase-iii-clinical-study-of-shr-4298-injection-in-patients-with-malignant-solid-tumors-100610594","NCT07229612","A Phase I\u002FII Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","A Multicenter, Open-label Phase I\u002FII Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.\n2. ECOG performance score of 0-1.\n3. Life expectancy ≥ 3 months.\n4. Have at least one measurable tumor lesion per RECIST v1.1.\n5. Patients with recurrent or metastatic solid tumors confirmed by histopathology and not amenable to radical surgery or radical chemoradiotherapy.\n6. Good level of organ function.\n7. Provide archived or fresh tumor tissue for vendor test.\n\nExclusion Criteria:\n\n1. Subjects with active central nervous system metastases or meningeal metastases.\n2. Suffering from other malignant tumors within five years before the first use of the drug.\n3. History of serious cardiovascular and cerebrovascular diseases.\n4. Clinically significant bleeding symptoms occurred within 3 months before the first dose of study drug.\n5. Subjects with uncontrolled tumor-related pain.\n6. Clinically uncontrollable third space effusion or third space effusion requiring intervention within 7 days before the first study treatment.\n7. Subjects who had a serious infection within 4 weeks before the first dose of the drug.\n8. History of immunodeficiency, including a positive HIV test or active hepatitis B or C.\n9. Subjects who received \\> 30 Gy of chest radiotherapy within 24 weeks before the first dose of the drug, subjects who received \\> 30 Gy of non-chest radiotherapy within 4 weeks before the first dose of the drug, and subjects who received ≤ 30 Gy of palliative radiation within 14 days before the first dose of the drug.\n10. Underwent major organ surgery within 28 days before the first dose of the drug.\n11. Those who are known to be allergic to any ingredients or excipients of SHR-4298 product.\n12. Administered a live attenuated vaccine within 28 days before the first dose.\n13. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.\n14. Per the investigator's judgment, there are any other circumstances that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate.",{"count":192,"type":21},200,[83,59],"This study is an open-label, multicenter Phase I\u002FII clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.",[25],"2025-11-13",{"date":198,"type":39},"2025-11-17",{"date":200,"type":21},"2025-11",{"date":202,"type":21},"2028-11",{"name":142,"class":97},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":57,"phases":214,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":163},"100241449","characterization-of-hyperpolarized-pyruvate-mri-reproducibility-100241449","NCT02421380","Characterization of Hyperpolarized Pyruvate MRI Reproducibility","Inclusion Criteria:\n\n* Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for patients with brain lesions. Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation.\n* Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and\u002For other tumor response criteria from an MSKCC IRB-approved clinical research protocol. NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment.\n* Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards \\& Guidelines), from assays obtained \\\u003C 2 weeks prior to study enrollment.\n* This study will include only patients with sarcoma, prostate, breast, brain, metastatic or pancreatic cancer. In the future other patient groups may be included through amendment of this protocol.\n\nExclusion Criteria:\n\n* Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of \\[1-13C\\] pyruvate injection)\n* Breast-feeding\n* Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)\n* Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay\n* Bilirubin \\> 1.5 x (ULN)\n* AST\u002FALT \\>2.5 x ULN\n* Albumin \\\u003C 3 g\u002Fdl\n* GGT \\> 2.5 x ULN if Alkaline phosphatase \\> 2.5 x ULN.\n* Renal: Creatinine \\>1.5 x ULN or creatinine clearance \\\u003C 60 mL\u002Fmin, from assays obtained within 3-4 weeks prior to study enrollment\n* Acute major illness (e.g., unstable cardiovascular condition, etc.)\n* Standard MRI exclusion criteria will also be applied, including pacemakers and metal clips located in the patient.","21 Years","90 Years",{"count":213,"type":21},109,[215],"NA","The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized \\[1-13C\\] pyruvate (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced. The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.",[25],[219,220,221],"Hyperpolarized Pyruvate","MRI","14-205","2025-11-05",{"date":224,"type":39},"2025-11-06",{"date":226,"type":39},"2015-04",{"date":228,"type":21},"2026-04",{"name":230,"class":71},"Memorial Sloan Kettering Cancer Center",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":57,"phases":240,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":72},"100602491","phase-3-nanocrystalline-megestrol-for-managing-chemotherapy-induced-nausea-and-vomiting-100602491","NCT07124195","Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","A Randomized, Controlled, Multicenter Clinical Study on the Whole-Process Management of Nanocrystalline Megestrol in Preventing Chemotherapy-Induced Nausea and Vomiting","Inclusion Criteria:\n\n* Aged ≥ 18 years, regardless of gender;\n* Histologically or cytologically confirmed malignant solid tumor;\n* No prior exposure to any chemotherapy drugs (antitumor drugs not used for cancer treatment, or intravesical instillation therapy for bladder cancer is not considered as chemotherapy);\n* Initially planned to receive single-day moderate to high emetogenic chemotherapy (MEC\u002FHEC) drugs;\n* Expected survival period ≥ 6 months;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n* Good organ function, meeting the following criteria:\n\n  1. Neutrophil count ≥ 1.5×10⁹\u002FL;\n  2. Hemoglobin ≥ 90 g\u002FL;\n  3. Platelet count ≥ 100×10⁹\u002FL;\n  4. Total bilirubin ≤ 1.5×ULN;\n  5. In patients without known liver metastasis, aspartate aminotransferase ≤ 2.5×ULN and\u002For alanine aminotransferase ≤ 2.5×ULN (for patients with liver metastasis, it can be relaxed to ≤ 5×ULN);\n  6. Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 50 ml\u002Fmin;\n  7. Electrocardiogram: QTc ≤ 450 ms (male), QTc ≤ 470 ms (female);\n  8. Echocardiogram: LVEF (left ventricular ejection fraction) ≥ 50%;\n* Female subjects of childbearing potential and male subjects whose partners are female of childbearing potential need to use a highly effective contraceptive method from the time of signing the informed consent form until 6 months after the last dose (see Appendix VII); female subjects of childbearing potential must have a negative blood pregnancy test within 72 hours before randomization; and must be non-lactating;\n* Clearly understand and voluntarily participate in the study, and sign the informed consent form in person.\n\nExclusion Criteria:\n\n* Having received abdominal (including the diaphragmatic plane and below) or pelvic radiotherapy within 7 days before enrollment, or planning to receive such radiotherapy within days 1 to 8 of treatment;\n* Planning to receive other moderate to high emetogenic chemotherapy drugs within days 2 to 8 after the first day of chemotherapy;\n* Planning to receive chemotherapy regimens including conventional paclitaxel (using castor oil as solvent);\n* Having taken drugs with potential antiemetic effects within 2 days before enrollment: 5-HT3 receptor antagonists (e.g., ondansetron, etc.), phenothiazines (e.g., prochlorperazine), butyrophenones (e.g., haloperidol), benzamides (e.g., metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, cyclizine, etc.;\n* Having started treatment with benzodiazepines or opioids within 2 days before enrollment (except for triazolam, temazepam or midazolam taken alone daily);\n* Subjects who started using morphine within 7 days before enrollment (except those taking a stable dose);\n* Having received systemic corticosteroid therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone or prednisolone) or sedative antihistamines (such as diphenhydramine) within 7 days before enrollment (Note: single use of steroids to prevent contrast agent allergy and local or inhaled administration are allowed);\n* Having used palonosetron within 14 days before enrollment;\n* Having used NK-1 receptor antagonists within 28 days before enrollment;\n* Having used specific CYP3A4 substrates (terfenadine, cisapride, astemizole) or CYP3A4 inhibitors (such as ritonavir, clarithromycin, ketoconazole or itraconazole, diltiazem, etc.) within 7 days before enrollment, and having used strong CYP3A4 inducers (such as phenobarbital, rifampicin, phenytoin and carbamazepine, etc.) or specific CYP2D6 substrates (thioridazine, pimozide) within 28 days before enrollment;\n* Having vomiting and\u002For retching, nausea within 24 hours before enrollment;\n* Subjects with symptomatic brain metastasis or any symptoms suggesting brain metastasis or intracranial hypertension;\n* Accompanied by poorly controlled serous cavity effusions, including pleural effusion, ascites, pericardial effusion (those controlled after treatment and stable for ≥ 2 weeks can be included);\n* Having severe cardiovascular diseases within 3 months before enrollment, including but not limited to acute myocardial infarction, unstable angina pectoris, significant valvular or pericardial diseases, history of ventricular tachycardia, symptomatic chronic heart failure (New York Heart Association \\[NYHA\\] class II to IV), history of severe cardiac conduction abnormalities (such as torsades de pointes);\n* Having poorly controlled hypertension before enrollment (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg at two consecutive resting measurements);\n* Complicated with active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), active hepatitis C (HCV-Ab positive, and HCV-RNA ≥ upper limit of normal), acquired immunodeficiency syndrome (AIDS) or positive HIV test, positive syphilis test;\n* Complicated with concomitant diseases that cannot take dexamethasone, such as active infection (e.g., pneumonia) or any uncontrolled diseases (e.g., diabetic ketoacidosis, gastrointestinal obstruction, etc.);\n* Known contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists or dexamethasone; history of thromboembolic diseases within the past 6 months;\n* Having participated in other clinical trials within 30 days before enrollment (based on the use of study drugs);\n* Subjects considered by the researcher to be unsuitable for participating in this study due to other conditions.",{"count":239,"type":21},126,[241],"PHASE3","The goal of this clinical trial is to learn if medroxyprogesterone acetate oral suspension (Meishiya®) works to prevent nausea and vomiting caused by single-day moderate to high emetogenic chemotherapy (MEC\u002FHEC) in the whole-process management. It will also learn about the safety of medroxyprogesterone acetate oral suspension (Meishiya®). The main questions it aims to answer are:\n\nDoes medroxyprogesterone acetate oral suspension (Meishiya®) effectively prevent nausea and vomiting induced by single-day MEC\u002FHEC in the whole-process management? What medical problems do participants have when taking medroxyprogesterone acetate oral suspension (Meishiya®)? Researchers will adopt a multicenter, randomized controlled, open-label trial design and compare the effects of medroxyprogesterone acetate oral suspension (Meishiya®) in preventing chemotherapy-induced nausea and vomiting.\n\nParticipants will be:\n\nStratified based on chemotherapy regimens (HEC vs MEC), gender (male vs female), and age (\\\u003C55 years vs ≥55 years) Planned to be 126 subjects who are first-time recipients of single-day MEC\u002FHEC for malignant solid tumors Take medroxyprogesterone acetate oral suspension (Meishiya®) as per the study protocol during the chemotherapy period Visit the research centers at specified intervals for checkups and assessments Record details of nausea, vomiting episodes, and any adverse reactions in a diary",[25,244],"Moderate to High Emetogenic Chemotherapy (MEC\u002FHEC) Drugs","2025-08-08",{"date":247,"type":39},"2025-08-15",{"date":249,"type":21},"2025-08-10",{"date":251,"type":21},"2026-12-31",{"name":253,"class":71},"The First Affiliated Hospital of Xinxiang Medical College",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":261,"targetDuration":4,"studyType":57,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":72},"100570078","the-effect-of-serum-ferritin-in-irae-100570078","NCT06702566","The Effect of Serum Ferritin in irAE","The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)","Inclusion Criteria:\n\nOnly patient who meet all the following conditions can be selected for this trial:\n\n1. Patients voluntarily sign informed consent;\n2. The age was 18-75 years old, and the gender was not limited;\n3. Patients with definitive diagnosis of malignant solid tumor or acute leukemia;\n4. Patients enrolled in will be treated with immunotherapy (including immuno- monotherapy，or immuno- plus targeted therapy, or immuno- plus chemotherapy), or targeted therapy (including targeted monotherapy, or targeted plus chemotherapy), or chemotherapy.\n5. The Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 or 2 for physical fitness;\n6. Sufficient bone marrow reserve at screening, defined as:\n\n   * Neutrophil absolute value (ANC) \\> 1.5 × 10\\^9\u002FL；\n   * Lymphocyte absolute value (ALC) ≥ 0.3 × 10\\^9\u002FL；\n   * Platelet (PLT) ≥ 100 × 10\\^9\u002FL；\n   * Hemoglobin (HGB) ≥ 100g \u002F L;\n7. The screening has appropriate organ function and meets the following criteria:\n\n   * Aspartate aminotransferase (AST) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);\n   * Alanine aminotransferase (ALT) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);\n   * Total serum bilirubin ≤ 1.5 times ULN (due to tumor infiltration ≤ 3 times ULN);\n   * Serum creatinine (SCR) ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60ml \u002F min;\n   * Have the lowest level of lung reserve, defined as ≤ grade 1 dyspnea and oxygen saturation \\> 91% in non oxygen breathing state;\n   * International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial prothrombin time (APTT) ≤ 1.5 times ULN;\n8. The urine pregnancy test of women of childbearing age is negative. Any male and female patient with fertility must agree to use effective contraceptive methods during the whole study and at least 1 year after the study treatment.\n\nExclusion Criteria:\n\nPatient who meet any of the following conditions well excluded in this trial:\n\n1. Active systemic autoimmune disease is known before screening and is under treatment;\n2. Those who stopped systemic hormone therapy for less than 2 weeks before enrollment；\n3. Those who have received organ \u002F tissue transplantation before screening;\n4. Those who meet any of the following conditions during screening:\n\n   * positive for hepatitis B surface antigen (HBsAg) and \u002F or hepatitis B e antigen (HBeAg);\n   * hepatitis B e antibody (HBE AB) and \u002F or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit;\n   * positive for hepatitis C antibody (HCV AB);\n   * positive anti Treponema pallidum antibody (TP AB);\n   * HIV antibody test positive;\n   * the copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit;\n5. The heart meets any of the following conditions during screening:\n\n   * left ventricular ejection fraction (LVEF) ≤ 50% (echo);\n   * New York Heart Association (NYHA) class III or IV congestive heart failure;\n   * hypertension (systolic blood pressure ≥ 140mmHg and \u002F or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension that has not been controlled by standard treatment;\n   * have had myocardial infarction or cardiac surgery within 12 months before cell transfusion;\n   * clinically significant valvular disease.\n6. There are clinical emergencies (such as intestinal obstruction or vascular compression) requiring urgent treatment due to tumor body obstruction or compression during screening;\n7. Patients with active bleeding during screening;\n8. Patients with deep venous thrombosis or pulmonary embolism within 6 months before screening;\n9. Those who received live vaccine within 6 weeks before screening;\n10. Patients with active infection and need treatment during screening;\n11. Poor compliance.",{"count":262,"type":21},1500,[215],"This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).",[266,25,267,268],"Immune-related Adverse Event","Acute Leukemia","Serum Ferritin","2024-11-21",{"date":271,"type":39},"2024-11-25",{"date":273,"type":39},"2024-07-04",{"date":275,"type":21},"2027-07-01",{"name":277,"class":71},"Tianjin Medical University Cancer Institute and Hospital",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":106,"enrollmentInfo":285,"targetDuration":4,"studyType":57,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":72},"100483764","early-phase-1-evaluate-the-safety-and-tolerability-of-jcxh-212-monotherapy-and-combined-with-toripalimab-in-the-treatment-of-malignant-solid-tumors-100483764","NCT05579275","Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","A Single-center, Open-label Study to Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","Inclusion Criteria:\n\n* The enrolled subjects shall meet all the following conditions at the same time:\n\n  1. male or female patients, aged 18 \\~ 75 years old;\n  2. patients with advanced malignant solid tumors who have failed standard treatment (progression or intolerance after treatment) confirmed by pathology and\u002For cytology (only for Part 1);\n  3. only for part2 : A. Patients with initial treatment, refusing or intolerant of standard treatment, PD-L1 (IHC 22C3) TPS ≥ 1%; B. Stage IIIB-IV patients with disease progression after previous standard treatment, who intend to receive immune monotherapy, can be enrolled regardless of the results of PD-L1; C. Stage II-III NSCLC patients after radical surgery, postoperative adjuvant chemotherapy (if necessary) has been completed, and PD-L1 (IHC 22c3) TPS is ≥ 1%, intend to receive adjuvant immunotherapy.\n  4. tumor biopsy tissue samples can be provided for tumor neoantigen detection;\n  5. ECOG (Eastern Cooperative Oncology Group) score of 0 \\~ 1 in general condition;\n  6. expected survival time of more than 3 months;\n  7. patients have at least one measurable tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECISTv1.1), the longest diameter at baseline is ≥ 10 mm (if lymph nodes, the short diameter is ≥ 15 mm);\n  8. patients shall have sufficient bone marrow reserve function, and have no liver and kidney coagulation dysfunction, and laboratory test values shall meet the following conditions:\n\n     1. absolute neutrophil count \\> 1.5 × 10\u002FL, And white blood cell count \\> 3 × 10\u002FL;\n     2. platelet count \\> 80 × 10\u002FL;\n     3. hemoglobin \\> 90 g\u002FL;\n     4. serum creatinine \\\u003C 1.5 × upper limit of normal (ULN) and creatinine clearance calculated by Cockroft-Gault formula \\> 30 mL\u002Fmin;\n     5. if there is no confirmed liver metastasis, AST, ALT \\\u003C 2.5 × ULN; if there is confirmed liver metastasis, AST, ALT \\\u003C 5 × ULN;\n     6. if there is no liver metastasis, total bilirubin \\\u003C 1.5 × ULN; if there is liver metastasis or Gilbert 's syndrome (hyperindirect bilirubinemia), total bilirubin \\\u003C 3 × ULN;\n     7. international normalized ratio (INR) \\\u003C 1.5, and activated partial thromboplastin time (APTT) \\\u003C 1.5 × ULN;\n  9. tumor tissue gene detection suggests that one or more vaccines contain positive tumor neoantigen expression;\n  10. patients do not have brain metastasis (except asymptomatic or stable brain metastasis after treatment for more than four weeks);\n  11. Any adverse reactions caused by previous treatment must have recovered to grade 0-1 (except alopecia and vitiligo) within 4 weeks before the first dose of study drug;\n  12. Patients voluntarily signed informed consent and expected compliance.\n\n      Exclusion Criteria:\n* Those meeting any of the following conditions may not be included.\n\n  1. Known or suspected hypersensitivity to the ingredients of the study drug or its analogues;\n  2. Only for Part 2: adverse reactions of grade ≥3 occurred after using ICIs in the past; except maculopapules \u002Fitching and reactive cutaneous capillary hyperplasia (RCCEP), there is no need to stop ICIs in hypothyroidism. Or those who are at high risk of receiving ICI treatment.\n  3. Patients with any other disease or medical condition that is unstable or may affect their safety or study compliance, any serious or uncontrolled systemic disease, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, active gastrointestinal ulcers, abnormal immune function, etc.;\n  4. Cardiovascular and cerebrovascular diseases\u002Fsymptoms\u002Findications that meet any of the following conditions:\n\n     1. mean resting QTc \\> 470 ms (corrected QT interval \\[corrected by Fridericia formula\\]), mean QTc of 3 ECGs, QT interval measurement should start from QRS complex to the end of T wave);\n     2. any clinically significant resting ECG abnormalities in rhythm, conduction or morphology, such as complete left bundle branch block, grade 2 and 3 heart block, PR interval \\> 250 ms, etc.;\n     3. any factor that increases the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, etc. or unexplained sudden death in a first-degree relative under 40 years of age, or any concomitant medication known to prolong the QT interval;\n     4. left ventricular ejection fraction (LVEF) \\\u003C 50%;\n     5. previous history of decreased myocardial contractility, i.e.Patients who presented with relevant symptoms within 6 months before study drug administration: such as chronic congestive heart failure, pulmonary edema or decreased cardiac ejection fraction;\n     6. patients who had a history of acute or chronic cardiovascular and cerebrovascular diseases and presented with relevant symptoms within 6 months before study drug administration: myocardial infarction, severe or unstable angina pectoris, cerebral infarction, cerebral hemorrhage, or transient ischemic attack;\n  5. . Patients who had an active second primary malignant tumor within 2 years before the first dose of study drug, except for specific cancers to be investigated and locally recurrent cancers that had undergone radical treatment (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ);\n  6. . Patients with uncontrollable malignant third space effusion;\n  7. . For women of childbearing age (postmenopausal women must have been postmenopausal for at least 12 months to be considered of non-childbearing potential), positive serum pregnancy test results within 7 days before the first dose of study drug;\n  8. Have received major surgery within 4 weeks before the first administration of the study drug; Before receiving the study drug for the first time, the elution period for previous anti-cancer treatments (chemotherapy, targeted drugs, immunotherapy and radiotherapy) or any other study treatment is less than 3 weeks or 5 half-lives, whichever is shorter.\n  9. Other serious, acute or chronic clinical or mental diseases or laboratory abnormalities that may increase the risk of research and drug use, or may interfere with the research results;\n  10. patients with active autoimmune diseases or history of autoimmune diseases but may relapse, but patients with the following diseases are not excluded and can be further screened:\n\n      1. type I diabetes;\n      2. hypothyroidism (if controlled with hormone replacement therapy alone);\n      3. controlled celiac disease;\n      4. skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia) ;\n      5. any other disease that does not recur in the absence of external triggers;\n  11. active human immunodeficiency virus (HIV), syphilis, hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, asymptomatic chronic hepatitis B or C carriers can be excluded; active HBV, HCV and HIV infection is defined as:\n\n      1. HBsAg positive and HBV DNA ≥ 1000 cps\u002Fml (or 200 IU\u002Fml);\n      2. anti-HCV antibody and HCV RNA positive;\n      3. HIV antibody positive;\n  12. Active infection and need anti-infection treatment;\n  13. Patients with a history of organ transplantation;\n  14. Any form of primary immunodeficiency (such as severe combined immunodeficiency disease);\n  15. Use of immunosuppressive drugs within 7 days before the first dose of study treatment, excluding: nasal spray, inhalation or other routes of local glucocorticoids or physiological doses of systemic glucocorticoids (that is, no more than 10mg\u002F day of prednisone or equivalent doses of other glucocorticoids); Short-term (≤7 days) use of prophylactic or therapeutic corticosteroids is allowed to avoid non-autoimmune allergic reactions (for example, pretreatment before intravenous contrast agent or drug administration);\n  16. The investigator believes that the patient is not suitable for this trial for any reason.",{"count":286,"type":21},24,[288],"EARLY_PHASE1","To evaluate the safety and tolerability of JCXH-212 monotherapy and combined with Toripalimab in patients with malignant solid tumors; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) of JCXH-212 monotherapy and combined with Toripalimab.",[25],"2024-05-12",{"date":293,"type":39},"2024-05-14",{"date":295,"type":39},"2023-02-06",{"date":297,"type":21},"2027-04-28",{"name":299,"class":71},"Peking University Cancer Hospital & Institute",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":17,"minAge":308,"maxAge":4,"enrollmentInfo":309,"targetDuration":311,"studyType":22,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":72},"100480722","biobank-and-register-of-patients-with-agresive-tumors-for-translational-and-analytical-research-100480722","NCT05539677","Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research","Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study","REGATA","Inclusion Criteria:\n\n* Signed inform consent\n* Histolgically verified solid tumour\n* Receiving systemic therapy for neoplasm\n* Has archival tumour tissue\n* Provide biosamples with living tumour tissue or blood samples for immunologic assessment\n\nExclusion Criteria:\n\n* Concurrent Lymphoprolipherative disorder\n* Patients after stem cell or bone marrow thansplantation\n* Incomplete informaton on previous cancer history or medical history\n* Patients with known primary immunodeficiency\n* Patients receiving immunosupressive therapy for concurrent illness\n* Pregnant patients","1 Year",{"count":310,"type":21},1000,"5 Years","The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies",[25,314,315,316,317,318,319],"Primary Brain Tumor","Melanoma","Soft Tissue Sarcoma","Colorectal Cancer","Kidney Cancer","Prostate Cancer","2024-05-03",{"date":322,"type":39},"2024-05-06",{"date":324,"type":39},"1998-09",{"date":326,"type":21},"2030-12",{"name":328,"class":71},"N.N. Petrov National Medical Research Center of Oncology"]